Vivus, Inc.: VVUS (NASDAQ)
MOUNTAIN VIEW, Calif.--April 4, 2002--VIVUS, Inc. (Nasdaq:VVUS), a pharmaceutical company developing innovative products to improve quality of life, today announced that it has begun treating patients in a clinical study designed to evaluate the safety and efficacy of TA-1790 for the treatment of erectile dysfunction (ED). TA-1790 is a fast acting, highly selective, potent, ORAL phosphodiesterase type 5 (PDE5) inhibitor. The study will be a multi-center, double-blind,placebo-controlled evaluation of TA-1790
See full release at: www.vivus.com
VIVUS, Inc. is a pharmaceutical company engaged in the development of innovative therapies for the treatment of quality-of-life disorders in men and women, with a focus on sexual dysfunction. Current development programs target Female Sexual Dysfunction (FSD), Erectile Dysfunction (ED) and Premature Ejaculation (PE). The Company developed
and markets in the U.S. MUSE(R) (alprostadil) and ACTIS(R), two innovations in the treatment of erectile dysfunction, and has partnered with Abbott Laboratories (NYSE:ABT) for the internationalmarketing and distribution of its male transurethral ED products. In Canada, VIVUS has partnered exclusively with Paladin Labs (TSE:PLB) to market and distribute MUSE.
CONTACT: VIVUS, Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates, Inc.
Bruce Voss, 310/691-7100 (Investors)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investors)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media)
egrabowski@lhai.com
www.lhai.com |
